Alzheimer’s disease touches every part of a person’s life — their memories, relationships, and sense of self. Though it changes how people live, it never changes who they are. At Eisai, we are inspired by the strength and humanity of those affected and are guided by their experiences as we work towards a more hopeful future for all.
Eisai is committed to driving meaningful change for people living with Alzheimer’s disease (AD) and their loved ones, as part of our pursuit of advancing the understanding of brain health. At Eisai, our work is underpinned by our hhc philosophy; putting patients, their families and care partners at the centre of all that we do.
Alzheimer’s is a neurodegenerative disease that becomes more severe over time.1,2 It accounts for 60 – 80% of all dementia cases.2
As AD symptoms progress, those impacted can often delay seeking medical advice for their symptoms due to fear or stigma, or a belief that AD is a normal part of the ageing process.3
AD also poses significant challenges to health systems and wider society.4,5 In Europe alone, it is estimated that approximately 50% of people living with dementia are undiagnosed.6
At Eisai, our work is focused on breaking down healthcare barriers surrounding AD to make a meaningful difference. We are committed to promoting better brain health, including prevention, diagnosis and management.
Advocating for earlier diagnosis
Delays in receiving a diagnosis means that those affected have less time to receive the care and support they need to adjust and plan for their future.
At Eisai, we recognise that by improving early detection of AD, interventions and support can be put in place, benefitting people with AD and their care partners. For change to happen, our healthcare systems and society need to adapt to newer models of care, which recognise the value of earlier AD diagnoses.
40 years of working in dementia
For over 40 years, we have been at the forefront of dementia research, discovering and developing the future generation of medicines.
We are investing in research that goes beyond treatments and spans from diagnostic tests to digital solutions, to improve the identification, screening, early diagnosis and management of AD.
Prioritising partnerships to achieve progress
Our experience has taught us that we cannot change the course of Alzheimer’s disease alone, and progress is accelerated through partnerships.
We prioritise listening to the unmet needs of people living with AD, their loved ones and society, building partnerships to accelerate change. We collaborate with industry, advocacy and healthcare partners, and invest in research to improve screening, early diagnosis and management of AD.
A human health care (hhc) approach to neurology
Understanding what is meaningful to those living with AD, requires an individualised approach to care that recognises everyone’s circumstances are different.
“It’s a tough path to be on, supporting a partner through this journey. The more knowledge about the condition that is known, the better each patient can be helped.” – AD care giver.
At Eisai, at least 1% of our working time is dedicated to actively listening to those impacted by various conditions to learn about their thoughts, feelings, hopes and fears. Learning from those with lived experiences of AD allows us to turn real life insights into actions that build a more dementia-friendly society.
1.Gustavsson A, et al., Alz Dement. 2023;19:658–670.; Alzheimer Europe. Prevalence of dementia in Europe.
2. Alzheimer’s Association. 2025 Alzheimer’s Disease Facts and Figures Special. Available at: www.alz.org/getmedia/ef8f48f9-ad36-48ea-87f9-b74034635c1e/alzheimers-facts-and-figures.pdf. Accessed December 2025.
3. Alzheimer’s Society. New research reveals one in three wait over a month to speak out about dementia worries. Available at: https://www.alzheimers.org.uk/news/2025-04-25/research-reveals-one-three-wait-over-month-speak-out-about-dementia-worries. Accessed December 2025.
4. European Brain Council. 2023. Rethinking Alzheimer’s Disease Detection and Diagnosis. Available at: https://www.braincouncil.eu/wp-content/uploads/2023/04/RETHINKAlzheimerDisease-Report_DEF3_HD_rvb_03042023.pdf. Last accessed: December 2025.
5. Meijer E., et al. Economic costs of dementia in 11 countries in Europe: Estimates from nationally representative cohorts of a panel study. Lancet Reg Health Eur. 2022;20:100445.
6. European Brain Council. Alzheimer’s Disease fact sheet. Available at: https://www.braincouncil.eu/wp-content/uploads/2015/07/Alzheimers-fact-sheet-July-2011.pdf. Accessed December 2025.
